Morgan Lewis

Kathleen M. Sanzo

Email: ksanzo@morganlewis.com
Washington, D.C.
1111 Pennsylvania Ave., NW
Washington, DC 20004-2541
Phone: 202.739.5209
Fax: 202.739.3001


Publications
Date Type Title
05/02/2012 Presentation Update on the Biosimilars Competition and Innovation Act: Overview and Life Cycle Planning for Biosimilars, presented at the BioNJ Diamond Circle Board of Trustees Meeting
04/02/2012 Outside Publication It’s Not Just Pill Mills The DEA Is After, Law360
03/09/2012 LawFlash/Client Alert Pharmacies and Suppliers Beware: It Is Not Just the Pill Mills They Are After
02/09/2012 LawFlash/Client Alert FDA Issues Three Draft Guidances for Biosimilars
01/11/2012 LawFlash/Client Alert FDA Gets (Un)Social
2011 Outside Publication Co-author, Prescription, Drug Promotions and Marketing, FDLI’s Food and Drug Law Regulation 2011, 2nd edition
05/23/2011 LawFlash/Client Alert FDA Requests Comments on the Development of a User Fee Program for Biosimilar and Interchangeable Biological Products
01/07/2011 LawFlash/Client Alert FDA Food Safety Modernization Act Summary
12/23/2010 LawFlash/Client Alert FDA Food Safety Modernization Act Greatly Expands FDA Enforcement Powers
11/30/2010 Outside Publication Utilizing REMS to Mitigate the Safety Risks of Pharmaceuticals: Perspectives on FDA Guidance, Lifecycle Management and Creating a New Scientific Discipline, FDLI Monograph Series
05/20/2010 Presentation Healthcare Reform—New Path for Biosimilars, presented at a Washington Legal Foundation Webcast
05/19/2010 Presentation May 2010 Health Care Reform Update, presented at a BioNJ Legal Breakfast Briefing, Bridgewater, NJ
04/26/2010 Presentation The Use of Social Media in Promotion of Medical Products, presented at PLI's Health Care 2010: Managing Risks in the New Compliance and Enforcement Environment Conference, New York
04/19/2010 Presentation Legal Issues Arising from REMS Programs, presented at the ACI REMS Conference, New York
04/15/2010 LawFlash/Client Alert Healthcare Reform Law: A New Regulatory Pathway for Biosimilar Biological Products
04/15/2010 LawFlash/Client Alert Healthcare Reform Law: Impact on Pharmaceutical Manufacturers
September 2009 Outside Publication The Ever-Widening Legal Morass Around Off-Label Communication, Washington Legal Foundation's Contemporary Legal Note Series, No. 63 (click here to read the article)
August 2009 Presentation Regulatory Considerations and Evolving Issues Concerning REMS Programs
06/18/2009 Presentation Life Sciences Summer Series: Drug and Device Off-Label Promotion (a Morgan Lewis Webinar)
03/25/2009 Presentation Regulatory and Litigation Strategies for Life Sciences Companies Post-Wyeth v. Levine, presented as a Morgan Lewis Webinar
03/05/2009 LawFlash/Client Alert U.S. Supreme Court Ruling in Wyeth v. Levine Rejects Preemption of Failure-to-Warn Claim
11/03/2008 LawFlash/Client Alert The Consumer Product Safety Improvement Act of 2008: Deputizing State Attorneys General and Plaintiffs’ Lawyers
06/19/2008 Presentation Regulatory and Legal Developments Concerning Clinical Trials, presented at the 2008 BIO International Convention, San Diego, CA
02/19/2008 Presentation Negotiating and Living with Consent Decrees, presented at the 6th Annual Food and Drug Law Institute Enforcement and Litigation Conference, Washington, D.C.
01/29/2008 Presentation State Perspectives on Existing and Future Regulations Surrounding Sales and Marketing, presented at the 5th Annual Pharmaceutical Marketing Compliance Congress, Washington, D.C.
12/06/2007 Presentation Assessing and Reducing Risks Associated with Medical Information/Product Information Communications, presented at ACI's 6th Managing Legal Risks and Avoiding Conflicts of Interest in Medical Affairs Conference, Philadelphia
06/19/2007 Presentation Proactive Steps Every Provider Should Take to Avoid Government Scrutiny, presented at ACI's Preparing for Government Healthcare Fraud Enforcement Conference, Washington, D.C.
06/18/2007 Outside Publication New Risks, New Plan: Drug Safety Concerns Show Need for Sophisticated Risk Management, Legal Times, Vol. 30, No. 25
05/17/2007 Presentation Compliant Models for Medical Device Grants, presented at CBI's Premier West Coast Conference on Bio/Pharmaceutical and Medical Device Grants, San Francisco
05/17/2007 Presentation Regulatory and Corporate Considerations in Life Sciences Industry Investments, presented at a Morgan Lewis Seminar, Palo Alto
04/17/2007 Presentation The AdvaMed Code of Ethics, presented at the AdvaMed MTLI Conference: The Regulation of Advertising, Promotion, and Sales of Medical Devices, Washington, D.C.
2007 Outside Publication Keys to Successful Interactions with Governing Bodies, Inside the Minds: Food and Drug Law Settlements and Negotiations
2006/07 Outside Publication Overview of Healthcare Fraud Investigations in the U.S., PLC Cross-border Life Sciences Handbook 2006/07
07/18/2006 Presentation Crossing Paths with the FDA—Regulatory Influence on the Defense of Drug and Device Products, presented at the Defense Research Institute Teleconference
03/29/2006 Presentation Generic Drug Issues: Authorized Generics, presented at the Temple University School of Pharmacy FDA/Industry Conference
03/07/2006 Presentation The New Medicare Act and Its Effects on Life Sciences Companies, presented to the New Jersey Technology Council Life Sciences Industry Network
2005/06 Outside Publication Overview of Healthcare Fraud Investigations in the U.S., PLC Cross-border Life Sciences Handbook
July/August 2004 Outside Publication New Medicare Act Provides New Competitive Landscape for the Pharmaceutical Industry, FDLI Update, Vol. 36
02/28/2003 Outside Publication FDA Must Clarify Drug Makers' Ability to Publicly Defend Products, Litigation Legal Foundation Legal Update, Vol. 13, No. 7
11/04/2002 Presentation Navigating a Pathway to FDA Approval
09/06/2002 Outside Publication FTC, Not FDA, Should Regulate Online Food Information, Legal Backgrounder, Vol. 17, No. 38
08/01/2002 Outside Publication FDA Challenges to Pharmaceutical Company Control of Product Lifecycle Management, FDLI Update
August 2002 Outside Publication Market Exclusivity: New Legal Developments and Pharmaceutical Marketing Implications, Regulatory Affairs Focus
04/23/2002 Presentation HIPAA: What Medical Device Firms Should Be Doing Now
04/01/2002 Presentation Be Wary of HP Lawsuits: Emerging Firms, presented to AvaMed, Washington, D.C.
March 2002 Outside Publication Pharmaceutical Pricing: System Changes And Global Effects, Metropolitan Corporate Counsel
02/01/2002 Presentation Corporate Response to CPSC Challenge - Legal, Technical, and Public Relations Issues, presented at the ICPHSO 9th Annual Meeting of the ABA Product Safety Seminar, Washington, D.C.
2003 Outside Publication Consumer Products Regulation (Chapter 13), Developments in Administrative Law and Regulatory Practice 2002-2003 (ABA Section on Administrative Law)
August 2001 Outside Publication U.S. Pharmaceutical Pricing: System Changes and Global Effects, Life Sciences Industry Report
January 2001 Outside Publication It's Worse Than You Think: US Regulatory Changes Require Pharmaceutical Company Attention, International Financial Law Review: Competition & Antitrust (Special IFLR Supplement)
January 2001 Morgan Lewis Title New Proposed Policy Regarding Imposition of Reporting Requirements on Products Sold Outside of the United States
12/01/2000 Presentation Regulatory Litigation in the Innovator Pharmaceutical Industry, presented at the FDLI's Conference on Hatch-Waxman: Past, Present and Future, Washington, D.C.
November 2000 Morgan Lewis Title California Trial Court Finds Ford Acted Fraudulently by Not Reporting Safety Information to Federal Agenices
09/04/2000 Outside Publication Expect Big Change in Drug Pricing System, The National Law Journal
June 2000 Outside Publication Providing Off-Label Use Information: New Decision Sends Industry One-Half Step Back, Regulatory Affairs Focus
02/01/2000 Presentation CPSC 15(b) Reporting Requirements: A Practical Guide to Knowing When and What to Report, presented to the American Bar Association, Orlando, FL
11/08/1999 Presentation Marketing Your Product as a Drug or Dietary Supplement: Legal Risks and Benefits:
Outline Presentation, The German-American Chamber of Commerce, Inc. and The Association of the German Pharmaceutical Industry Conference on the Regulatory Framework for OTC Drugs and Dietary Supplements, Washington, D.C.
06/29/1999 Presentation Medical Device Update, presented to the Food and Drug Law Institute, Washington, D.C.
12/07/1998 Outside Publication Strategies for Obtaining Market Exclusivity for Genetic Discoveries: Patent, FDA, and Contract Mechanisms, Decision Resources, Inc.
January 1998 Outside Publication FDA Takes Important Step Toward Liberalizing Its Direct-to-Consumer Broadcast Advertising Policy, Food, Drug, Cosmetic and Medical Device Law Digest, Vol. 15, No. 1
November 1997 Outside Publication New FDA Regulations Implementing the Dietary Supplement Health and Education Act of 1994, Legal Mind, Vol. 164, Japan
05/22/1997 Presentation Voluntary Standards for Consumer Products - An Antitrust Checklist, presented to the American Bar Association, Section of Administrative Law and Regulatory Practice, Washington, D.C.
November 1996 Outside Publication U.S. Product Liability and Preemption Under the Medical Device Amendments: The Business Implications of the Supreme Court's Medtronic Decision, Legal Mind, Vol. 152, Japan
09/17/1996 Presentation Regrouping and Responding After a Failed New Drug Pre-Approval Inspection by the FDA, presented at the Conference for the Institute for International Research, Philadelphia
08/01/1996 Morgan Lewis Title Product Liability and Preemption Under the Medical Device Amendments: The Business Implications of Medtronic, Inc. v. Lohr
1996 Outside Publication Recalls of Consumer Products in U.S. Distribution, Product Safety (First Edition) (London)
April 1994 Outside Publication Legal Considerations in Agreements for Manufacturing and Distribution of Biotechnology Products, Legal Mind (Japan), Vol. 121
03/01/1994 Morgan Lewis Title Reinvigorated Regulation of Consumer Product Safety Commission Expected with Confirmation of New Chair:
ML&B White Paper
02/13/1994 Presentation The Relationship Between Product Tampering and Product Liability, presented at Closure Manufacturers Association Annual Meeting, Washington, D.C.
11/08/1993 Presentation Checklist of Legal Considerations in Agreements for Manufacturing and Distribution of Biotechnology Products, presented at the Biotechnology and Business Conference, Prague, Czech Republic
September 1993 Outside Publication The Admissibility of 'Junk Science' Evidence: Regulatory Effects, Regulatory Affairs Professionals Society News
09/01/1992 Morgan Lewis Title New Federal Reporting Regulations for Consumer Products:
ML&B White Paper
11/01/1991 Morgan Lewis Title Consumer Product Defects -- New Federal Reporting Obligations Concerning Product Liability Lawsuits and Injuries Caused By Consumer Products:
ML&B White Paper
01/01/1991 Morgan Lewis Title New Federal Reporting Obligations Concerning Defects in Consumer Products:
ML&B White Paper
June 1990 Outside Publication U.S. Product Liability Considerations For Exposure To Pesticides From Food, Legal Mind (Japan), Vol. 76